The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy

Endokrynologia Polska

Volumn 68, Issue 1, 2017, Pages 26-34

  Wojciechowska, Celina ^a   Jacheć, Wojciech ^a   Romuk, Ewa ^a   Nowalany Kozielska, Ewa ^a   Tomasik, Andrzej ^a   Siemińska, Lucyna ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b School of Medicine   (Poland)

Author keywords

Adiponectin; BMI; Dilated cardiomyopathy; Heart failure; Leptin

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LEPTIN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SODIUM; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NONISCHEMIC CARDIOMYOPATHY; PREDICTION; PROBABILITY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; BLOOD; CARDIOMYOPATHY, DILATED;

ADIPONECTIN; ADULT; BODY MASS INDEX; CARDIOMYOPATHY, DILATED; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 85015845326     PISSN: 0423104X     EISSN: 22998306     Source Type: Journal    
DOI: 10.5603/EP.2017.0005     Document Type: Article

References (30)

1. Merlo M, Pivetta A, Pinamonti B, et al. Long-Term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014; 16(3): 317-324, doi: 10.1002/ejhf.16
2. Dorner TE, Rieder A. Obesity paradox in elderly patients with cardiovascular diseases. Int J Cardiol. 2012; 155(1): 56-65, doi: 10.1016/j. ijcard.2011.01.076
3. Marques MB, Langouche L. Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. Crit Care Med. 2013; 41(1): 317-325, doi: 10.1097/CCM.0b013e318265f21c
4. Schulze PC, Kratzsch J, Linke A S et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5: 33-40.
5. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003; 108(6): 754-759, doi: 10.1161/01. CIR.0000083716.82622.FD
6. Bobbert P, Jenke A, Bobbert T, et al. High leptin and resistin expression in chronic heart failure: Adverse outcome in patients with dilated and inflammatory cardiomyopathy. Eur J Heart Fail. 2012; 14(11): 1265-1275, doi: 10.1093/eurjhf/hfs111
7. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006; 92(10): 1420-1424, doi: 10.1136/hrt.2005.083345
8. Sharma A, Lavie CJ, Borer JS, et al. Meta-Analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015; 115(10): 1428-1434, doi: 10.1016/j.amjcard.2015.02.024
9. Krysiak R, Sierant M, Marek B et al. The effect of angiotensin-converting enzyme inhibitors on plasma adipokine leveles in normotensive patients with coronary artery disease. Endokrynol Pol 2010; 61: 280-7.
10. Bienek R, Marek B, Kajdaniuk D, et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol. 2012; 63(5): 338-345
11. Martin SS, Blaha MJ, Muse ED et al. Leptin and incident cardiovascular disease: The Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015; 239: 67-72.
12. Hall ME, Harmancey R, Stec DE. Lean heart: Role of leptin in cardiac hypertrophy and metabolism. World J Cardiol. 2015; 7(9): 511-524, doi: 10.4330/wjc.v7.i9.511
13. Wannamethee SG, Whincup PH, Lennon L, et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007; 167(14): 1510-1517, doi: 10.1001/archinte.167.14.1510
14. Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care. 2009; 32(4): 612-616, doi: 10.2337/dc08-1596
15. Tajmir P, Ceddia RB, Li RK, et al. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase-And phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology. 2004; 145(4): 1550-1555, doi: 10.1210/en.2003-1128
16. Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation. 2004; 110(10): 1269-1275, doi: 10.1161/01. CIR.0000140766.52771.6D
17. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1): 79-83
18. Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003; 23(1): 85-89
19. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005; 112(12): 1756-1762, doi: 10.1161/CIRCULATIONAHA.104.530972
20. Bogomolovas J, Brohm K, Celutkiene J, et al. Induction of Ankrd1 in Dilated Cardiomyopathy Correlates with the Heart Failure Progression. Biomed Res Int. 2015; 2015: 273936, doi: 10.1155/2015/273936
21. Tamura T, Furukawa Y, Taniguchi R, et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J. 2007; 71(5): 623-630
22. Yin WH, Wei J, Huang WP, et al. Prognostic value of circulating adipokine levels and expressions of adipokines in the myocardium of patients with chronic heart failure. Circ J. 2012; 76(9): 2139-2147
23. Shibata R, Izumiya Y, Sato K, et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol. 2007; 42(6): 1065-1074, doi: 10.1016/j.yjmcc.2007.03.808
24. Takahashi T, Saegusa S, Sumino H, et al. Adiponectin replacement therapy attenuates myocardial damage in leptin-deficient mice with viral myocarditis. J Int Med Res. 2005; 33(2): 207-214
25. Skurk C, Wittchen F, Suckau L, et al. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J. 2008; 29(9): 1168-1180, doi: 10.1093/eurheartj/ehn136
26. Melenovsky V, Kotrc M, Borlaug BA, et al. Relationships between right ventricular function, body composition, and prognosis in advanced heart failure. J Am Coll Cardiol. 2013; 62(18): 1660-1670, doi: 10.1016/j. jacc.2013.06.046
27. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109(5): 594-600, doi: 10.1161/01. CIR.0000112582.16683.EA
28. Horwich TB, Hamilton MA, Fonarow GC. B-Type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol. 2006; 47(1): 85-90, doi: 10.1016/j.jacc.2005.08.050
29. Polak J, Kotrc M, Wedellova Z, et al. Lipolytic effects of B-Type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol. 2011; 58(11): 1119-1125, doi: 10.1016/j. jacc.2011.05.042
30. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999; 353(9167): 1838-1842, doi: 10.1016/S0140-6736(98)09286-1